New Atmosphere, New Vision: Gibson and Whittemore Kick Off Invest in ME Conference 2016
Mark Berry reports on Dr. Gibson's introduction and Dr. Whittemore's keynote speech, at the 11th Invest in ME International ME Conference in London.
Discuss the article on the Forums.

Rituximab in CFS - as a psychotherapy.

Discussion in 'Rituximab: News and Research' started by RogerBlack, Jul 30, 2017.

  1. RogerBlack

    RogerBlack Senior Member

    Messages:
    896
    Likes:
    2,896
    Assuming for the moment that you believe CFS is entirely according to the fear-avoidance model, and ...
    Has anyone compared the efficacies of it in the phase II trial, compared with the various CBT approaches.
    They are both (if you believe in the BPS model) cognitive/placebo driven unblinded trials.

    I don't of course believe this is the mechanism of action, but was idly wondering how it would compare if you treated it as a placebo effect driven treatment, with regards to cost-efficacy and ...
     
  2. Jonathan Edwards

    Jonathan Edwards "Gibberish"

    Messages:
    5,250
    Likes:
    32,017
    The phase II trial was blinded so the difference between rituximab and control cannot easily be considered a placebo effect.
     
  3. JES

    JES Senior Member

    Messages:
    547
    Likes:
    893
    Furthermore, it seems that the majority of people responded around the 6 months mark after receiving their first Rituximab infusion, so it would be very difficult to attribute a placebo effect to these improvements.
     
    Gingergrrl, JaimeS, John Mac and 3 others like this.
  4. A.B.

    A.B. Senior Member

    Messages:
    3,750
    Likes:
    23,195
    Assuming the phase 3 trial is positive, anyone that still thinks the challenge of treating ME/CFS effectively is that of generating the strongest placebo effect is making a fool of themselves.

    A positive result will change the game and former CBT/GETLP/etc proponents will have to either adapt and start treating the psychosocial problems that patients actually have or leave the ME/CFS field.
     
    mango and Valentijn like this.
  5. RogerBlack

    RogerBlack Senior Member

    Messages:
    896
    Likes:
    2,896
    Oops - I thought the phase II was unblinded, but I was thinking of the 2015 paper, not the 2011 one.

    To ignore results of phase III tips over from the threadbare excuse territory, into active denialism. (which I expect, but hope is ignored).
     
  6. Londinium

    Londinium Senior Member

    Messages:
    178
    Likes:
    1,420
    It is, however, a criticism that I imagine might be made around the Cyclophosphamide trial. I would think it's very difficult to argue proper double blinding around a drug like Cyclophosphamide given its side effects - which is why it's important that the team are also using objective measures in addition to self-report. And, unlike PACE, that these objective measures are in line with the self-reporting scores.

    (As noted above it's the delay in response that, to me, indicates it's unlikely to be placebo response, especially as in the first trial a response was expected earlier by the researchers than actually occurred - indeed, the trial was technically a failure when measured on its primary objective because it measured response too early).
     
    Woolie and MEMum like this.
  7. tomcy6

    tomcy6

    Messages:
    13
    Likes:
    47
    I think that by the time you get to Rituximab you will have tried so many treatments (prescription and nonprescription) and had so many changes in symptoms that your placebo effect capacity will have been used up.
     
  8. Kenny Banya

    Kenny Banya Senior Member

    Messages:
    321
    Likes:
    527
    Australia
    Ha ha ha!!
    Brilliant!!!
    Stand up worthy material !!!!
     
    Little Bluestem likes this.
  9. Kenny Banya

    Kenny Banya Senior Member

    Messages:
    321
    Likes:
    527
    Australia
    Taking this logic to its conclusion, we might as well label any successful treatment for any disease as potentially the placebo effect.
    But then, that is why we have treatment, placebo & no treatment groups & test the data for statistical significance (off the top of my head they will be using a Repeated Measures ANOVA for this drug trial).
     

See more popular forum discussions.

Share This Page